NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free IMTX Stock Alerts $10.96 +0.15 (+1.39%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$10.59▼$10.9650-Day Range$9.78▼$12.2552-Week Range$7.15▼$13.16Volume288,137 shsAverage Volume483,595 shsMarket Capitalization$927.87 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immatics alerts: Email Address Immatics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.0% Upside$16.00 Price TargetShort InterestBearish10.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.32) to ($1.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 starsMedical Sector711th out of 918 stocksBiological Products, Except Diagnostic Industry115th out of 152 stocks 3.5 Analyst's Opinion Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmatics has only been the subject of 1 research reports in the past 90 days.Read more about Immatics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.50% of the outstanding shares of Immatics have been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 21.4, which indicates bearish sentiment.Change versus previous monthShort interest in Immatics has recently decreased by 0.89%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMTX. Previous Next 3.2 News and Social Media Coverage News SentimentImmatics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Immatics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IMTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Immatics is held by insiders.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immatics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($1.32) to ($1.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -10.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -10.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immatics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Immatics Stock (NASDAQ:IMTX)Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More IMTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMTX Stock News HeadlinesMay 18 at 5:02 AM | americanbankingnews.comImmatics Expected to Earn FY2024 Earnings of ($0.85) Per Share (NASDAQ:IMTX)May 17 at 2:12 AM | americanbankingnews.comQ2 2024 EPS Estimates for Immatics (NASDAQ:IMTX) Lifted by AnalystMay 16 at 11:02 PM | markets.businessinsider.comBuy Rating Affirmed for Immatics on Strong TCR-T Cell Therapy Data and Promising OutlookMay 16 at 8:00 AM | msn.comStock Market News for May 15, 2024May 14, 2024 | globenewswire.comImmatics Announces First Quarter 2024 Financial Results and Business UpdateMay 12, 2024 | americanbankingnews.comImmatics (NASDAQ:IMTX) Sees Large Volume IncreaseMay 8, 2024 | americanbankingnews.comImmatics (NASDAQ:IMTX) Stock Price Down 0.2%March 29, 2024 | markets.businessinsider.comMaintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising PartnershipsMarch 21, 2024 | investorplace.comIMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | globenewswire.comImmatics Announces Full Year 2023 Financial Results and Corporate UpdateMarch 15, 2024 | finance.yahoo.comWith 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big gunsMarch 10, 2024 | seekingalpha.comCantor sees strong year ahead for oncology M&AMarch 10, 2024 | msn.comCantor Fitzgerald sees strong year ahead for oncology M&AMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic PartnershipsFebruary 28, 2024 | seekingalpha.comEditas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must WatchFebruary 6, 2024 | uk.yahoo.comBolton TV star to 'go back to Fernandos one last time' as he spreads the loveFebruary 3, 2024 | finance.yahoo.comImmatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last yearFebruary 3, 2024 | seekingalpha.comImmatics: Pioneering TCR Therapies In The Fight Against CancerJanuary 17, 2024 | msn.comImmatics commences public offering of sharesJanuary 17, 2024 | finance.yahoo.comImmatics Announces Pricing of $175 Million Public OfferingJanuary 17, 2024 | finance.yahoo.comImmatics Announces Proposed Public OfferingNovember 20, 2023 | markets.businessinsider.comPositive Clinical Progress and Promising Pipeline Underpin Buy Rating for Immatics (IMTX): An Analysis of Graig Suvannavejh’s RecommendationNovember 16, 2023 | markets.businessinsider.comImmatics: Strong Buy Rating Supported by Promising Clinical Results and Upcoming CatalystsNovember 14, 2023 | markets.businessinsider.comImmatics Announces Third Quarter 2023 Financial Results and Business UpdateNovember 8, 2023 | finanznachrichten.deImmatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialSee More Headlines Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/18/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMTX CUSIPN/A CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees432Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+46.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,980,000.00 Net Margins-107.80% Pretax Margin-106.01% Return on Equity-29.36% Return on Assets-15.95% Debt Debt-to-Equity RatioN/A Current Ratio3.95 Quick Ratio2.87 Sales & Book Value Annual Sales$58.44 million Price / Sales15.88 Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book2.13Miscellaneous Outstanding Shares84,660,000Free Float81,864,000Market Cap$927.87 million OptionableOptionable Beta0.69 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Harpreet Singh Ph.D. (Age 49)CEO, MD, Member of Management Board & Executive Director Comp: $884.46kDr. Toni Weinschenk Ph.D. (Age 50)Co-Founder & Chief Innovation Officer Mr. Arnd Christ MBA (Age 58)Chief Financial Officer Mr. Steffen Walter Ph.D. (Age 47)Chief Operations Officer Mr. Edward A. Sturchio J.D. (Age 48)General Counsel & Secretary Dr. Carsten Reinhardt M.D. (Age 57)Ph.D., Chief Development Officer Mr. Cedrik M. Britten M.D. (Age 48)Chief Medical Officer Mr. Jordan Silverstein (Age 44)Head of Strategy Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardMr. Ephraim Hofsäß M.Sc.Vice President of SEC Reporting & AccountingMore ExecutivesKey CompetitorsProKidneyNASDAQ:PROKAutolus TherapeuticsNASDAQ:AUTLBioCryst PharmaceuticalsNASDAQ:BCRXScholar RockNASDAQ:SRRKRelay TherapeuticsNASDAQ:RLAYView All CompetitorsInstitutional OwnershipRA Capital Management L.P.Bought 1,750,000 shares on 5/17/2024Ownership: 2.067%Zimmer Partners LPBought 187,000 shares on 5/17/2024Ownership: 0.469%Janus Henderson Group PLCSold 66,437 shares on 5/16/2024Ownership: 0.754%Lazard Asset Management LLCSold 2,474 shares on 5/15/2024Ownership: 0.007%Torno Capital LLCSold 82,800 shares on 5/15/2024Ownership: 0.000%View All Institutional Transactions IMTX Stock Analysis - Frequently Asked Questions Should I buy or sell Immatics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMTX shares. View IMTX analyst ratings or view top-rated stocks. What is Immatics' stock price target for 2024? 2 Wall Street analysts have issued 1-year price targets for Immatics' shares. Their IMTX share price targets range from $16.00 to $16.00. On average, they anticipate the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 46.0% from the stock's current price. View analysts price targets for IMTX or view top-rated stocks among Wall Street analysts. How have IMTX shares performed in 2024? Immatics' stock was trading at $10.53 at the beginning of the year. Since then, IMTX stock has increased by 4.1% and is now trading at $10.96. View the best growth stocks for 2024 here. When is Immatics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 15th 2024. View our IMTX earnings forecast. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) posted its earnings results on Thursday, March, 21st. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.09. The business had revenue of $17.14 million for the quarter, compared to the consensus estimate of $11.78 million. Immatics had a negative net margin of 107.80% and a negative trailing twelve-month return on equity of 29.36%. What ETFs hold Immatics' stock? ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX). Who are Immatics' major shareholders? Immatics' stock is owned by many different institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (7.61%), Price T Rowe Associates Inc. MD (3.81%), RA Capital Management L.P. (2.07%), Wasatch Advisors LP (0.86%), Janus Henderson Group PLC (0.75%) and StemPoint Capital LP (0.58%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMTX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
